Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABO1108
- Development stage
- Phase 2
- Lead developer
- Abogen Bioscience
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ABO1108 is a lyophilized messenger RNA (mRNA) vaccine candidate developed by Suzhou Abogen Biosciences for the prevention of herpes zoster (shingles). The vaccine encodes a structurally optimized version of the varicella-zoster virus (VZV) glycoprotein E (gE), which is the primary target for neutralizing antibodies and T-cell responses. Utilizing Abogen's proprietary nucleoside base modification technology and formulated with lipid nanoparticles (LNPs) containing a domestically developed ionizable lipid, ABO1108 is unique for its advanced lyophilized formulation. This freeze-dried state allows the vaccine to remain stable at standard refrigeration temperatures (2-8°C), providing a significant logistical advantage over conventional liquid mRNA vaccines that require ultra-cold storage. It is currently being evaluated in Phase 2 clinical trials for safety and immunogenicity in adults aged 40 years and older.
- Other names
- Lyophilized Herpes Zoster mRNA VaccineSuzhou Abogen Herpes Zoster Vaccine
02
Targets
gE (VZV glycoprotein E)
Beyond the preview
Go deeper on ABO1108.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABO1108.